SMAD4 and neuroblastoma: The Smad4 immunoreactivity was significantly lower in NB cases with poor differentiation (P < 0.001), higher mitosis karyorrhexis index (MKI) (P = 0.002), and advanced international neuroblastoma staging system (INSS) stages (P = 0.016) (Supplementary Table S1).